Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$12.23
-0.9%
$11.91
$10.45
$21.69
$4.32B0.56691,205 shs525,067 shs
Envista Holdings Co. stock logo
NVST
Envista
$18.99
+2.9%
$17.09
$14.22
$23.00
$3.22B0.992.56 million shs1.79 million shs
Penumbra, Inc. stock logo
PEN
Penumbra
$260.63
+1.6%
$275.71
$148.00
$310.00
$10.09B0.49451,117 shs874,400 shs
Solventum Co. stock logo
SOLV
Solventum
$74.44
+0.9%
$69.98
$47.16
$85.92
$12.88B0.541.20 million shs655,608 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.00%+5.79%+5.08%-19.65%-18.04%
Envista Holdings Co. stock logo
NVST
Envista
0.00%-1.76%+1.08%+7.49%+4.36%
Penumbra, Inc. stock logo
PEN
Penumbra
0.00%-0.98%-8.82%-7.22%+36.49%
Solventum Co. stock logo
SOLV
Solventum
0.00%-1.63%-0.64%-1.91%+34.92%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
4.2659 of 5 stars
4.13.00.00.01.61.73.8
Envista Holdings Co. stock logo
NVST
Envista
3.3872 of 5 stars
2.22.00.03.82.70.01.9
Penumbra, Inc. stock logo
PEN
Penumbra
4.6246 of 5 stars
3.45.00.03.71.52.51.9
Solventum Co. stock logo
SOLV
Solventum
0.4554 of 5 stars
1.04.00.00.02.20.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
2.23
Hold$15.5427.13% Upside
Envista Holdings Co. stock logo
NVST
Envista
2.33
Hold$20.236.56% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.88
Moderate Buy$302.4016.03% Upside
Solventum Co. stock logo
SOLV
Solventum
2.09
Hold$80.297.86% Upside

Current Analyst Ratings Breakdown

Latest NVST, SOLV, PEN, and BLCO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$19.00 ➝ $16.00
6/6/2025
Solventum Co. stock logo
SOLV
Solventum
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Weight
5/27/2025
Envista Holdings Co. stock logo
NVST
Envista
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/27/2025
Envista Holdings Co. stock logo
NVST
Envista
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$21.00 ➝ $23.00
5/19/2025
Solventum Co. stock logo
SOLV
Solventum
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$78.00 ➝ $87.00
5/9/2025
Solventum Co. stock logo
SOLV
Solventum
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$80.00 ➝ $78.00
5/6/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$18.00 ➝ $12.00
5/5/2025
Envista Holdings Co. stock logo
NVST
Envista
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$21.00 ➝ $18.00
5/2/2025
Envista Holdings Co. stock logo
NVST
Envista
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$21.00
5/2/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $15.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $13.00
(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$4.83B0.90$1.45 per share8.41$18.57 per share0.66
Envista Holdings Co. stock logo
NVST
Envista
$2.50B1.29$1.47 per share12.91$17.04 per share1.11
Penumbra, Inc. stock logo
PEN
Penumbra
$1.24B8.14$2.48 per share105.01$29.88 per share8.72
Solventum Co. stock logo
SOLV
Solventum
$8.31B1.55N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
-$317M-$1.03N/A12.730.85-6.62%3.35%1.66%7/30/2025 (Estimated)
Envista Holdings Co. stock logo
NVST
Envista
-$1.12B-$6.53N/A15.691.27-44.56%3.86%2.21%8/6/2025 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$90.95M$1.06766.5552.022.831.17%9.74%7.35%7/29/2025 (Estimated)
Solventum Co. stock logo
SOLV
Solventum
N/A$2.1634.4613.561.94N/AN/AN/A8/4/2025 (Estimated)

Latest NVST, SOLV, PEN, and BLCO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Solventum Co. stock logo
SOLV
Solventum
$1.19$1.34+$0.15$0.78$2.02 billion$2.07 billion
5/1/2025Q1 2025
Envista Holdings Co. stock logo
NVST
Envista
$0.20$0.24+$0.04$0.10$608.17 million$616.90 million
4/30/2025Q1 2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$0.03-$0.07-$0.10-$0.60$1.15 billion$1.15 billion
4/23/2025Q1 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.66$0.83+$0.17$1.00$315.72 million$324.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Envista Holdings Co. stock logo
NVST
Envista
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Solventum Co. stock logo
SOLV
Solventum
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.72
1.60
1.01
Envista Holdings Co. stock logo
NVST
Envista
0.44
2.04
1.76
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.01
3.25
Solventum Co. stock logo
SOLV
Solventum
2.45
1.15
0.83

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
11.07%
Envista Holdings Co. stock logo
NVST
Envista
N/A
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Solventum Co. stock logo
SOLV
Solventum
N/A

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.76%
Envista Holdings Co. stock logo
NVST
Envista
1.30%
Penumbra, Inc. stock logo
PEN
Penumbra
4.20%
Solventum Co. stock logo
SOLV
Solventum
0.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
12,500353.72 million351.94 millionOptionable
Envista Holdings Co. stock logo
NVST
Envista
12,700169.49 million169.95 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
3,90038.73 million36.59 millionOptionable
Solventum Co. stock logo
SOLV
Solventum
22,000173.01 millionN/AOptionable

Recent News About These Companies

KeyCorp Initiates Coverage on Solventum (NYSE:SOLV)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$12.22 -0.11 (-0.85%)
Closing price 03:58 PM Eastern
Extended Trading
$12.20 -0.03 (-0.20%)
As of 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Envista stock logo

Envista NYSE:NVST

$18.99 +0.54 (+2.91%)
Closing price 03:59 PM Eastern
Extended Trading
$18.98 -0.01 (-0.03%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Penumbra stock logo

Penumbra NYSE:PEN

$260.63 +4.13 (+1.61%)
Closing price 03:59 PM Eastern
Extended Trading
$260.98 +0.36 (+0.14%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Solventum stock logo

Solventum NYSE:SOLV

$74.44 +0.64 (+0.86%)
Closing price 03:58 PM Eastern
Extended Trading
$74.47 +0.03 (+0.05%)
As of 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.